OPNT - Opiant Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Opiant Pharmaceuticals, Inc.

233 Wilshirre Boulevard
Suite 280
Santa Monica, CA 90401
United States

Full Time Employees16

Key Executives

NameTitlePayExercisedYear Born
Dr. Roger CrystalCEO & Director1.38MN/A1976
Mr. David D. O'TooleChief Financial Officer539.25kN/A1959
Dr. Phil SkolnickChief Scientific Officer814.09kN/A1947
Lisa SherSr. Director of Investor Relations & CommunicationsN/AN/AN/A
Mr. Rahsaan ThompsonGen. CounselN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; eating disorders, including bulimia nervosa and binge eating disorders; alcohol use disorders; acute cannabinoid overdose; opioid use disorders; and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.

Corporate Governance

Opiant Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.